FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563933574> ?p ?o ?g. }

• W2563933574 endingPage "1371" @default.
• W2563933574 startingPage "1363" @default.
• W2563933574 abstract "BACKGROUND No consensus exists regarding the use of radiotherapy (RT) in conjunction with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with relapsed/refractory classical Hodgkin lymphoma (HL). The objectives of the current study were to characterize practice patterns and assess the efficacy and toxicity of RT at 2 major transplantation centers. METHODS Eligible patients underwent HDC/ASCT from 2006 through 2015 using the combination of either carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) or cyclophosphamide, BCNU, and etoposide (CBV). RESULTS For the cohort of 189 patients, the 4-year overall survival rate was 80%, the progression-free survival rate was 67%, and the local control (LC) rate was 68%. RT was used within 4 months of ASCT for 22 patients (12%) and was given more often for disease that was early stage, primary refractory, or [18F]fluorodeoxyglucose (FDG)-avid at the time of HDC/ASCT. Disease recurrence occurring after HDC/ASCT was associated with primary refractory disease and FDG-avidity at the time of HDC/ASCT. RT was not found to be associated with LC, progression-free survival, or overall survival on univariate analysis. In a model incorporating primary refractory HL and FDG-avid disease at the time of HDC/ASCT, RT was found to be associated with a decreased risk of local disease recurrence (hazard ratio, 0.3; P = .02). In patients with primary refractory HL and/or FDG-avid disease at the time of HDC/ASCT, the 4-year LC rate was 81% with RT versus 49% without RT (P = .03). There was one case of Common Terminology Criteria for Adverse Events grade ≥ 3 RT-related toxicity (acute grade 3 pancytopenia). CONCLUSIONS In patients undergoing ASCT for relapsed/refractory HL, peritransplantation RT was used more often for disease that was early stage, primary refractory, or FDG-avid after salvage conventional-dose chemotherapy. RT was associated with improved LC of high-risk localized disease and was well tolerated with modern techniques. Cancer 2017;123:1363–1371. © 2016 American Cancer Society." @default.
• W2563933574 created "2017-01-06" @default.
• W2563933574 creator A5007688820 @default.
• W2563933574 creator A5009745981 @default.
• W2563933574 creator A5009933533 @default.
• W2563933574 creator A5029237145 @default.
• W2563933574 creator A5037784199 @default.
• W2563933574 creator A5039052702 @default.
• W2563933574 creator A5059256779 @default.
• W2563933574 creator A5071173748 @default.
• W2563933574 creator A5084997480 @default.
• W2563933574 creator A5085712310 @default.
• W2563933574 creator A5088286702 @default.
• W2563933574 creator A5090230371 @default.
• W2563933574 creator A5091294211 @default.
• W2563933574 date "2016-12-16" @default.
• W2563933574 modified "2023-09-30" @default.
• W2563933574 title "A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation" @default.
• W2563933574 cites W1768406053 @default.
• W2563933574 cites W2001744336 @default.
• W2563933574 cites W2006178875 @default.
• W2563933574 cites W2026188656 @default.
• W2563933574 cites W2035881466 @default.
• W2563933574 cites W2037668591 @default.
• W2563933574 cites W2062486240 @default.
• W2563933574 cites W2080313054 @default.
• W2563933574 cites W2089158135 @default.
• W2563933574 cites W2115707980 @default.
• W2563933574 cites W2122636885 @default.
• W2563933574 cites W2122654415 @default.
• W2563933574 cites W2133201432 @default.
• W2563933574 cites W2141164659 @default.
• W2563933574 cites W2145917992 @default.
• W2563933574 cites W2157717016 @default.
• W2563933574 cites W2164814247 @default.
• W2563933574 cites W2171187650 @default.
• W2563933574 cites W2324389148 @default.
• W2563933574 cites W2473773035 @default.
• W2563933574 cites W2979525510 @default.
• W2563933574 cites W94237140 @default.
• W2563933574 doi "https://doi.org/10.1002/cncr.30482" @default.
• W2563933574 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5811230" @default.
• W2563933574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27984652" @default.
• W2563933574 hasPublicationYear "2016" @default.
• W2563933574 type Work @default.
• W2563933574 sameAs 2563933574 @default.
• W2563933574 citedByCount "19" @default.
• W2563933574 countsByYear W25639335742017 @default.
• W2563933574 countsByYear W25639335742018 @default.
• W2563933574 countsByYear W25639335742019 @default.
• W2563933574 countsByYear W25639335742020 @default.
• W2563933574 countsByYear W25639335742021 @default.
• W2563933574 countsByYear W25639335742022 @default.
• W2563933574 countsByYear W25639335742023 @default.
• W2563933574 crossrefType "journal-article" @default.
• W2563933574 hasAuthorship W2563933574A5007688820 @default.
• W2563933574 hasAuthorship W2563933574A5009745981 @default.
• W2563933574 hasAuthorship W2563933574A5009933533 @default.
• W2563933574 hasAuthorship W2563933574A5029237145 @default.
• W2563933574 hasAuthorship W2563933574A5037784199 @default.
• W2563933574 hasAuthorship W2563933574A5039052702 @default.
• W2563933574 hasAuthorship W2563933574A5059256779 @default.
• W2563933574 hasAuthorship W2563933574A5071173748 @default.
• W2563933574 hasAuthorship W2563933574A5084997480 @default.
• W2563933574 hasAuthorship W2563933574A5085712310 @default.
• W2563933574 hasAuthorship W2563933574A5088286702 @default.
• W2563933574 hasAuthorship W2563933574A5090230371 @default.
• W2563933574 hasAuthorship W2563933574A5091294211 @default.
• W2563933574 hasBestOaLocation W25639335742 @default.
• W2563933574 hasConcept C121332964 @default.
• W2563933574 hasConcept C126322002 @default.
• W2563933574 hasConcept C141071460 @default.
• W2563933574 hasConcept C142424586 @default.
• W2563933574 hasConcept C143998085 @default.
• W2563933574 hasConcept C144301174 @default.
• W2563933574 hasConcept C207103383 @default.
• W2563933574 hasConcept C2776694085 @default.
• W2563933574 hasConcept C2778119113 @default.
• W2563933574 hasConcept C2778684742 @default.
• W2563933574 hasConcept C2779050716 @default.
• W2563933574 hasConcept C2780147359 @default.
• W2563933574 hasConcept C2780739268 @default.
• W2563933574 hasConcept C2911091166 @default.
• W2563933574 hasConcept C38180746 @default.
• W2563933574 hasConcept C44249647 @default.
• W2563933574 hasConcept C71924100 @default.
• W2563933574 hasConcept C87355193 @default.
• W2563933574 hasConceptScore W2563933574C121332964 @default.
• W2563933574 hasConceptScore W2563933574C126322002 @default.
• W2563933574 hasConceptScore W2563933574C141071460 @default.
• W2563933574 hasConceptScore W2563933574C142424586 @default.
• W2563933574 hasConceptScore W2563933574C143998085 @default.
• W2563933574 hasConceptScore W2563933574C144301174 @default.
• W2563933574 hasConceptScore W2563933574C207103383 @default.
• W2563933574 hasConceptScore W2563933574C2776694085 @default.
• W2563933574 hasConceptScore W2563933574C2778119113 @default.
• W2563933574 hasConceptScore W2563933574C2778684742 @default.
• W2563933574 hasConceptScore W2563933574C2779050716 @default.

• next